The NSW government will spend $16m for a free vaccination scheme to combat respiratory syncytial virus in babies, starting ...

Regarding hospitalizations among immunocompetent older adults, vaccine effectiveness was 83% for the GSK vaccine and 73% for ...

Respiratory syncytial virus (RSV) is the most important cause of infantile bronchiolitis and pneumonia. It is ubiquitous, with most children acquiring their primary infection within the first year ...

Current guidelines recommend that pregnant people receive a vaccine against respiratory syncytial virus (RSV) -- which typically causes mild, cold-like symptoms in most adults but can be deadly for ...

As cold and flu season ramps up, the most vulnerable among us need extra protection. Infants are among the most susceptible ...

In three months, the distribution of RSV vaccines will begin in the Americas, according to a PAHO announcement.

But there’s another virus out there that can also cause these symptoms: It’s called respiratory syncytial virus (RSV), and even if you’ve never heard of it before, there’s a very good ...

Timely diagnosis of RSV is imperative for optimal patient management; by rapidly identifying RSV infection, health professionals can implement appropriate infection control measures while limiting ...

Respiratory syncytial virus, or RSV, is a virus that causes infections of the lungs and breathing passages. It is highly ...

The highly contagious respiratory syncytial virus (RSV) typically causes mild illness, but it can lead to severe respiratory complications, particularly for at-risk individuals. Drawing on local ...

Current guidelines recommend that pregnant people receive a vaccine against respiratory syncytial virus (RSV)-;which typically causes mild, cold-like symptoms in most adults but can be deadly for ...

On Tuesday, the FDA approved Pfizer Inc’s (NYSE:PFE) Abrysvo (Respiratory Syncytial Virus Vaccine), the company’s bivalent RSV prefusion F (RSVpreF) vaccine, to prevent lower respiratory tract ...